MLP Assay for Arrestin-AP2 Inhibitors
MLP Assay for Arrestin-AP2 Inhibitors
批准号:
8208096
负责人:
Eric R Prossnitz
金额:
$3.78万
依托单位国家:
美国
项目类别:
财政年份:
2011
资助国家:
美国
项目状态:
已结题
起止时间:
2011-01-01 至 2012-12-31
关键词:
Adaptor Signaling ProteinApoptosisApoptoticArrestinsBindingBiologicalBiological AssayCapsid ProteinsCellsClathrinCollectionDiseaseDown-RegulationEarEndosomesFamilyFlow CytometryFundingG Protein-Coupled Receptor SignalingG-Protein-Coupled ReceptorsGTP-Binding ProteinsGlutathioneGoalsHumanHuman BiologyLeftLigand BindingMediatingMitogen-Activated Protein KinasesMolecularMolecular ProbesNew MexicoPathway interactionsPeptidesPhosphotransferasesPhysiologyPlayProteinsPublicationsReceptor ActivationRecyclingRegulationResearchResearch PersonnelRoleSRC geneSignal PathwaySignal TransductionSignaling ProteinSystemTherapeuticTranscription Factor AP-2 AlphaUniversitiesVesiclearrestin 2basecancer celldesensitizationexperiencefMet-Leu-Phe receptorformyl peptidehuman diseaseinhibitor/antagonistnovelpreventpublic health relevancereceptorreceptor bindingreceptor functionreceptor internalizationsmall moleculetherapeutic developmenttooltrafficking
中文摘要
描述(由申请人提供):G蛋白偶联受体(GPCR)在人类生理和疾病的几乎每一个方面都发挥着关键作用。Arrestin蛋白在许多这些途径中起着至关重要的作用。Arrestin与GPCRs的磷酸化形式结合,阻止受体与G蛋白结合并激活,导致脱敏。此外,对许多GPCRs来说,arrestin作为内化和“二级”信号转导的适配分子发挥作用。Arrestin通过直接与笼状蛋白和接头AP-2结合的结构域来调节内化。抑制素还可以与激活酶和其他信号蛋白结合。我们最近的结果已经确定了arrestin和AP-2之间的特定分子相互作用,这对于回收某些GPCRs是至关重要的。我们还表明,破坏这种相互作用会导致许多GPCR的快速凋亡途径。到目前为止,还没有已知的小分子来调节arrestin及其相互作用的蛋白质之间的相互作用。我们已经建立了一种高通量的流式细胞术分析AP-2和一个荧光花青素多肽。这项拟议研究的主要目标是确定调控Arrestin和AP-2之间相互作用的化合物,从而调节GPCR运输、信号传递和细胞凋亡。抑制这种相互作用的小分子将是一个有价值的工具,以评估AP-2在可能的数百个GPCR的arrestin依赖的调节中的作用,并可能通过其诱导疾病细胞凋亡的能力代表治疗开发的基础。
与公共卫生相关:受体在人类生物学和疾病的几乎每一个方面都发挥着至关重要的作用。受体的活性和功能是由大量相互作用的蛋白质介导的。最大的一类受体是G蛋白偶联受体(GPCR)家族。Arrestin蛋白在抑制和激活GPCRs信号转导过程中起着关键作用。我们已经确定了arrestin和细胞蛋白AP-2之间的特定相互作用。到目前为止,还没有已知的小分子来调节arrestin及其相互作用的蛋白质之间的相互作用。拟议研究的目标是确定抑制或刺激Arrestin和AP-2之间相互作用的化合物,以提供一个有价值的工具来评估这种相互作用在调节数百个GPCRs中的作用。这种分子将对该领域的研究人员大有裨益,并能够在过度刺激的疾病细胞(如癌细胞)中诱导凋亡,从而找到治疗用途。
英文摘要
DESCRIPTION (provided by applicant): G protein-coupled receptors (GPCR) play a critical role in almost every aspect of human physiology and disease. The protein arrestin plays a vital role in many of these pathways. Arrestin binds to the phosphorylated form of GPCRs and prevents the receptor from binding to and activating G proteins, resulting in desensitization. In addition, for many GPCRs, arrestin functions as an adapter molecule for internalization as well as "secondary" signaling. Arrestin mediates internalization via a domain that binds directly to clathrin and the adapter AP-2. Arrestins also bind to kinases and other signaling proteins. Our recent results have identified a specific molecular interaction between arrestin and AP-2 that is critical for the recycling certain GPCRs. We have also shown that disrupting this interaction induces a rapid apoptotic pathway for many GPCRs. To date there are no small molecules known that regulate interactions between arrestin and its interacting proteins. We have developed a high throughput flow cytometric assay involving AP-2 and a fluorescent arrestin peptide. The primary goal of the proposed research is to identify compounds that regulate the interaction between arrestin and AP-2, resulting in modulation of GPCR trafficking, signaling and apoptosis. A small molecule that inhibits this interaction will be a valuable tool to assess the role of AP-2 in the arrestin-dependent regulation of potentially hundreds of GPCRs and could represent the basis for therapeutic development through its ability to induce apoptosis in disease cells.
PUBLIC HEALTH RELEVANCE: Receptors play a vital role in almost every aspect of human biology and disease. Receptor activity and function are mediated by a large collection of interacting proteins. The largest class of receptors is the G protein-coupled receptor (GPCR) family. The protein arrestin plays a critical role in both inhibiting and activating signaling by GPCRs. We have identified a specific interaction between arrestin and the cellular protein AP-2. To date there are no small molecules known that regulate interactions between arrestin and its interacting proteins. The goal of the proposed research is to identify compounds that inhibit or stimulate the interaction between arrestin and AP-2 to provide a valuable tool to assess the role of this interaction in the regulation of hundreds of GPCRs. Such a molecule would be of great benefit for researchers in the field and could find therapeutic utility in its ability to induce apoptosis in hyper stimulated disease cells such as cancer cells.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
G protein-coupled estrogen receptor GPER and breast carcinogenesis
-
批准号:8517052
-
项目类别:
-
资助金额:$29.45万
-
财政年份:2012
-
负责人:Eric R Prossnitz
-
依托单位:
G protein-coupled estrogen receptor GPER and breast carcinogenesis
-
批准号:8677811
-
项目类别:
-
资助金额:$30.39万
-
财政年份:2012
-
负责人:Eric R Prossnitz
-
依托单位:
Assay Implementation
-
批准号:8443194
-
项目类别:
-
资助金额:$9.83万
-
财政年份:2012
-
负责人:Eric R Prossnitz
-
依托单位:
G protein-coupled estrogen receptor GPER and breast carcinogenesis
-
批准号:10472699
-
项目类别:
-
资助金额:$34.69万
-
财政年份:2012
-
负责人:Eric R Prossnitz
-
依托单位:
G protein-coupled estrogen receptor GPER and breast carcinogenesis
-
批准号:10251268
-
项目类别:
-
资助金额:$35.39万
-
财政年份:2012
-
负责人:Eric R Prossnitz
-
依托单位:
G protein-coupled estrogen receptor GPER and breast carcinogenesis
-
批准号:8849761
-
项目类别:
-
资助金额:$31.33万
-
财政年份:2012
-
负责人:Eric R Prossnitz
-
依托单位:
G protein-coupled estrogen receptor GPER and breast carcinogenesis
-
批准号:10689300
-
项目类别:
-
资助金额:$19.11万
-
财政年份:2012
-
负责人:Eric R Prossnitz
-
依托单位:
G protein-coupled estrogen receptor GPER and breast carcinogenesis
-
批准号:9079447
-
项目类别:
-
资助金额:$31.33万
-
财政年份:2012
-
负责人:Eric R Prossnitz
-
依托单位:
MLP Assay for Arrestin-AP2 Inhibitors
-
批准号:8069438
-
项目类别:
-
资助金额:$3.77万
-
财政年份:2011
-
负责人:Eric R Prossnitz
-
依托单位:
Womens Cancers Research Program
-
批准号:8180647
-
项目类别:
-
资助金额:$5.29万
-
财政年份:2010
-
负责人:Eric R Prossnitz
-
依托单位:
Assay Implementation
-
批准号:8116589
-
项目类别:
-
资助金额:$43.42万
-
财政年份:2010
-
负责人:Eric R Prossnitz
-
依托单位:
Assay Implementation
-
批准号:8344436
-
项目类别:
-
资助金额:$44.11万
-
财政年份:2008
-
负责人:Eric R Prossnitz
-
依托单位:
The Role of GPR30 in Advanced Endometrial Cancer
-
批准号:7265917
-
项目类别:
-
资助金额:$28.5万
-
财政年份:2007
-
负责人:Eric R Prossnitz
-
依托单位:
The Role of GPR30 in Advanced Endometrial Cancer
-
批准号:7488362
-
项目类别:
-
资助金额:$28.5万
-
财政年份:2007
-
负责人:Eric R Prossnitz
-
依托单位:
The Role of GPR30 in Advanced Endometrial Cancer
-
批准号:7617585
-
项目类别:
-
资助金额:$28.5万
-
财政年份:2007
-
负责人:Eric R Prossnitz
-
依托单位:
A novel intracellular 7TM estrogen receptor in breast
-
批准号:7776955
-
项目类别:
-
资助金额:$25.85万
-
财政年份:2006
-
负责人:Eric R Prossnitz
-
依托单位:
A novel intracellular 7TM estrogen receptor in breast
-
批准号:7585193
-
项目类别:
-
资助金额:$25.85万
-
财政年份:2006
-
负责人:Eric R Prossnitz
-
依托单位:
A novel intracellular 7TM estrogen receptor in breast
-
批准号:7244227
-
项目类别:
-
资助金额:$25.85万
-
财政年份:2006
-
负责人:Eric R Prossnitz
-
依托单位:
A novel intracellular 7TM estrogen receptor in breast
-
批准号:7099898
-
项目类别:
-
资助金额:$26.63万
-
财政年份:2006
-
负责人:Eric R Prossnitz
-
依托单位:
A novel intracellular 7TM estrogen receptor in breast
-
批准号:7384996
-
项目类别:
-
资助金额:$25.85万
-
财政年份:2006
-
负责人:Eric R Prossnitz
-
依托单位:
国内基金
海外基金
登录
查看更多内容
Epac1/2通过蛋白酶体调控中性粒细胞NETosis和Apoptosis在急性肺损伤中的作用研究
-
批准号:LBY21H010001
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2020
-
负责人:郑绪阳
-
依托单位:
基于Apoptosis/Ferroptosis双重激活效应的天然产物AlbiziabiosideA的抗肿瘤作用机制研究及其结构改造
-
批准号:81703335
-
项目类别:青年科学基金项目
-
资助金额:20.0万元
-
批准年份:2017
-
负责人:卫高菲
-
依托单位:
双肝移植后Apoptosis和pyroptosis在移植物萎缩差异中的作用和供受者免疫微环境变化研究
-
批准号:81670594
-
项目类别:面上项目
-
资助金额:58.0万元
-
批准年份:2016
-
负责人:陈昊
-
依托单位:
Serp-2 调控apoptosis和pyroptosis 对肝脏缺血再灌注损伤的保护作用研究
-
批准号:81470791
-
项目类别:面上项目
-
资助金额:73.0万元
-
批准年份:2014
-
负责人:董家鸿
-
依托单位:
Apoptosis signal-regulating kinase 1是七氟烷抑制小胶质细胞活化的关键分子靶点?
-
批准号:81301123
-
项目类别:青年科学基金项目
-
资助金额:23.0万元
-
批准年份:2013
-
负责人:王海莲
-
依托单位:
APO-miR(multi-targeting apoptosis-regulatory miRNA)在前列腺癌中的表达和作用
-
批准号:81101529
-
项目类别:青年科学基金项目
-
资助金额:22.0万元
-
批准年份:2011
-
负责人:陈雪芹
-
依托单位:
放疗与细胞程序性死亡(APOPTOSIS)相关性及其应用研究
-
批准号:39500043
-
项目类别:青年科学基金项目
-
资助金额:9.0万元
-
批准年份:1995
-
负责人:梁克
-
依托单位: